Folic Acid Supplementation in Children With Sickle Cell Disease

Status Completed

Clinical Trial Summary

Folic acid supplementation (1mg/d) is the standard recommendation for Canadian children with Sickle cell disease (SCD), even though it can provide up to six times the recommended intake amount for healthy children. There is growing concern that too much folic acid can be detrimental to health as high folate levels and circulating unmetabolized folic acid (UMFA), which occurs in blood with doses of folic acid as low as 0.2mg/d, have been associated with accelerated growth of some pre-cancerous cells, and altered DNA methylation and gene expression. To inform the efficacy and potential harm of high-dose folic acid supplementation in Canadian children with SCD, a double-blind randomized controlled cross-over trial is proposed. Children with SCD (n=36, aged 2-19 y) will be recruited from BC Children's Hospital and randomized to initially receive 1 mg/d folic acid or a placebo for 12-weeks (wk). After a 12-wk washout period, treatments will be reversed.

Clinical Trial Description

Blood samples will be collected at baseline and 12-wk of each treatment period (weeks 12, 24, and 36). Serum and RBC concentrations of total folate, different folate forms and clinical outcomes will be measured at baseline and after each treatment period. Dietary folate intake will be assessed at baseline. The objective of this study is to determine efficacy and potential harm of folic acid supplementation, versus no supplementation, in Canadian children with sickle cell disease. It is hypothesized that: (1) there will be no difference in mean RBC folate concentrations across folic acid and placebo groups after 12-wk, (2) none of the participants will have folate deficiency, and (3) compared to periods of no supplementation, during periods of high-dose folic acid supplementation participants will show no difference in clinical outcomes, but have higher plasma unmetabolized folic acid concentrations. Significance: There is a need to determine if the current clinical practice of high-dose folic acid supplementation is efficacious, and warranted. ;

Study Design

Related Conditions & MeSH terms

Anemia, Sickle Cell

Clinical Trial Details

NCT number	NCT04011345
Study type	Interventional
Source	University of British Columbia
Contact
Status	Completed
Phase	N/A
Start date	November 23, 2020
Completion date	October 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06078696` - Siplizumab for Sickle Cell Disease Transplant	Phase 1/Phase 2
Completed	`NCT04134299` - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease	N/A
Completed	`NCT02561312` - Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
Completed	`NCT00890396` - Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
Completed	`NCT00059293` - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Terminated	`NCT00034528` - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia	Phase 2
Completed	`NCT00005277` - Cooperative Study of The Clinical Course of Sickle Cell Disease	N/A
Active, not recruiting	`NCT04170348` - Daily Vitamin D for Sickle-cell Respiratory Complications	Phase 2
Completed	`NCT04584528` - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease	N/A
Recruiting	`NCT02286154` - Therapeutic Response Evaluation and Adherence Trial (TREAT)	N/A
Completed	`NCT02857023` - Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease	N/A
Withdrawn	`NCT01925001` - Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis	Phase 2
Terminated	`NCT00122980` - Stroke With Transfusions Changing to Hydroxyurea	Phase 3
Completed	`NCT00246077` - Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport	N/A
Completed	`NCT00094887` - Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises	Phase 2
Completed	`NCT00035763` - Pain in Sickle Cell Epidemiologic Study	N/A
Terminated	`NCT04091737` - CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease	Phase 1
Completed	`NCT00005300` - Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease	N/A
Recruiting	`NCT04351698` - SMILES: Study of Montelukast in Sickle Cell Disease	Phase 2/Phase 3
Not yet recruiting	`NCT06290401` - A Socio-ecological Approach for Improving Self-management in Adolescents With SCD	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.